Presentation and outcome of COVID-19 in HIV patients with high viral loads and opportunistic infections: a case series

Yasmine O. Hardy1, Divine A. Amenuke2, Kojo A. Hutton-Mensah3, David R. Chadwick4 and Rita Larsen-Reindorf5

Ghana Med J 2020; 54(4) supplement: 121-124 doi: http://dx.doi.org/10.4314/gmj.v54i4s.20

1Department of Medicine, Komfo Anokye Teaching Hospital/School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana
2Department of Medicine, Komfo Anokye Teaching Hospital/School of Medical Sciences, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana
3Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana
4Department of Infectious Diseases, South Tees Hospitals NHS Foundation Trust, Centre for Clinical Infections, Middlesbrough, United Kingdom
5Ashanti Regional Health Directorate, Ghana Health Service, Kumasi, Ghana

Corresponding author: Yasmine Oladele Hardy E-mail: yasminehardy_1999@yahoo.com

Conflict of interest: None declared

SUMMARY
Coronavirus disease 2019 (COVID-19) is especially severe in patients with underlying chronic conditions, with increased risk of mortality. There is concern that people living with HIV (PLWH), especially those with severe immunosuppression, and COVID-19 may have severe disease and a negative clinical outcome. Most studies on COVID-19 in PLWH are from Asia, Europe and America where population dynamics, antiretroviral treatment coverage and co-existing opportunistic infections may differ from that in sub-Saharan Africa. We report on the clinical profile and outcome of three cases of PLWH co-infected with SARS-CoV-2. They all presented with fever, cough and breathlessness and also had advanced HIV infection as evidenced by opportunistic infections, high HIV viral loads and low CD4 counts. The patients responded favourably to the standard of care and were discharged home. Our findings suggest that PLWH with advanced immunosuppression may not necessarily have an unfavourable disease course and outcome. However, case-controlled studies with a larger population size are needed to better understand the impact of COVID-19 in this patient population.

Keywords: COVID-19, advanced HIV, clinical outcome, SARS-CoV-2, Ghana

Funding: Not declared

INTRODUCTION
SARS-CoV-2 infection may present with severe manifestations such as acute respiratory distress syndrome, septic shock and respiratory failure; especially in the elderly and those with co-morbidities.1 The risk of succumbing to infections, including viral respiratory infections, in people living with HIV (PLWH) is driven by abnormal immune mediated responses as a result of HIV-related immunosuppression.2,3 This risk is higher in patients with advanced disease.2,3 Nevertheless, some studies have reported favourable outcomes of COVID-19 in PLWH.4,5 To the best of our knowledge most of these studies are from well-resourced settings4-6 and the findings may vary from reports from sub-Saharan Africa due to differences in population dynamics, co-existing opportunistic infection burden and antiretroviral therapy (ART) coverage. In a bid to help fill this research gap, we describe the presentation and outcome of three cases of PLWH with advanced HIV disease at the Highly Infectious Isolation Unit (HIIU) of the Komfo Anokye Teaching Hospital in Kumasi, Ghana. They were referred from peripheral facilities and had confirmed COVID-19 infection by SARS-CoV-2 polymerase chain reaction on nasopharyngeal swabs.

CASE REPORTS

Ethical approval and patient consent
Ethical approval (reference no. KATH-IRB/AP/067/20) was obtained from the Institutional Review Board of the Komfo Anokye Teaching Hospital.

Patient 1
A 53-year-old ART naïve, HIV positive man (time of diagnosis unknown) with Kaposi’s sarcoma was admitted at the HIIU.
His complaints were fever and cough of two weeks duration and breathlessness of a day’s duration. On systemic review he admitted to sore throat, breathlessness on exertion, chest pain, dysphagia and odynophagia. On examination, he had oral candidiasis, was afebrile (37.3°C) and respiratory rate was 28 cycles/min. Oxygen saturation (SpO₂) was 92% in room air and rose to 98% on intranasal oxygen at 5L/min. Glasgow Coma Score was 14/15.

His chest X-ray revealed patchy, ground-glass opacities in the left lung field mostly in the middle zone with superimposed consolidation on the opacities. His electrocardiogram (ECG) was normal with a corrected QT interval (QTc) of 0.31 sec. Full blood count revealed moderate hypochromic, microcytic anaemia. Hypoalbuminaemia was noted in the liver panel. CD4 count was 78 cells/microliter and HIV viral load 27,210 copies/ml (Table1).

He was treated with oral hydroxychloroquine 200mg t.i.d., flucloxacilone 150mg daily, prophylactic dose (960mg daily) of co-trimoxazole, tenofovir/lamivudine (one tablet daily) and lopinavir/ritonavir two tablets b.d.; 40mg daily of zine, multivitamins one tablet b.d. and 1g daily of Vitamin C. He was put on a nutritious diet and psycho-social counselling was provided by a psychiatrist.

On day 4, his SpO₂ was 98% on room air and he was weaned off oxygen. On day 7 most of his presenting symptoms had subsided and his GCS was 15/15. He continued to clinically improve. An ECG done following completion of hydroxychloroquine on day 10 showed elevation of QTc to 0.5 sec; patient was, however, asymptomatic. Two repeat PCR tests for SARS –CoV-2 RNA were done (on days 11 and 12) on nasal wash samples and rectal swab taken 24 hours apart. His PCR results came out negative on day 17 and he was discharged on that day to continue ART care on outpatient basis. He has since been reintegrated into his community by the District Health Management Team and is doing well.

**Patient 2**

A 64-year-old woman who had defaulted her ART for about 9 months presented with a 3-month history of recurrent cough productive of yellowish sputum, fever, breathlessness, night sweats, weight loss, and dizziness. She was pale, cachectic, dehydrated and hypotensive (blood pressure of 69/49mmHg). SpO₂: 98% on room air.

Chest X-ray showed tracheal deviation to the right, decreased lung volume and lower zone consolidation on the right with compensatory hypertrophy on the left. These findings were suggestive of pulmonary tuberculosis.

A right apical cavity with a mass within suggestive of a fungal ball was also evident. Sputum GeneXpert was negative for mycobacterium tuberculosis. Her ECG was normal with a QTc of 0.42 sec. Blood workup yielded anaemia, thrombocytopenia and hypoalbuminaemia (Table 1). Escherichia coli, sensitive to gentamycin, was isolated on urine culture.

On day 2, she developed symptoms of anaemia and was transfused with 3 units of blood with improvement of symptoms. Blood pressure rose to 109/74mmHg. She was given intravenous fluids, intravenous gentamycin - 80mg t.i.d., oral hydroxychloroquine 200mg t.i.d., trimozolone 200mg b.d., three tablets daily of a fixed dose combination of isoniazid, rifampicin, pyrazinamide, ethambutol (HRZE), 100mg daily of pyridoxine, prophylactic dose of co-trimoxazole, multivitamins (1 b.d.), 40mg daily of zine, 1g daily of Vitamin C and a well-balanced diet. Psychosocial support was offered, and an ART counsellor provided adherence counselling.

On day 7 she developed bilateral cellulitis of her lower limbs and intravenous amoxicillin/clavulanic acid (1.2g t.i.d.) and analgesics were started. On day 10 her symptoms had subsided with marked improvement in the cellulitis so intravenous amoxicillin/clavulanic acid was changed to oral 1000mg b.d.

PCR tests for SARS –CoV-2 RNA (nasal wash and rectal swab) done on days 11 and 12, after completion of hydroxychloroquine, were negative. Repeat ECG showed a QTc of 0.49 sec. On day 14 of taking HRZE she was initiated on a fixed dose combination of tenofovir, lamivudine and efavirenz (1 nocte). The patient was discharged on day 17 to continue outpatient TB/HIV care.

**Patient 3**

A 28-year-old newly diagnosed HIV positive male was admitted at HIIU with a 2-week history of cough productive of whitish sputum, fever, weight loss, drenching night sweats, anorexia, fatigue and palpitations. On examination he was febrile with a temperature of 39.2°C, pale and moderately dehydrated. There were matted axillary lymph nodes approximately 3.5cm x 3.5 cm which were non-tender and mobile. He had tachycardia at a rate of 116beats/min and hypotension with a blood pressure of 79/57mmHg. His SpO₂ on room air was 98%. A chest X-ray revealed bilateral, peripheral, ground- glass opacities in the middle and lower zones on the left suggestive of COVID-19 infection. There was sinus tachycardia on ECG.

Laboratory investigations (Table 1) showed microcytic anaemia, elevated alanine and aspartate transaminases, hypoalbuminaemia, elevated urea and creatinine levels.
with increased urea/creatinine ratio suggestive of an acute kidney injury likely from dehydration. GeneXpert of the sputum done on day 2 detected mycobacterium tuberculosis. He was given intravenous and oral fluids, oral hydroxychloroquine 200mg t.i.d., prophylactic dose of co-trimoxazole, antituberculous medications [4 tabs of a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol (HRZE)], pyridoxine 100mg daily, multivitamins 1 b.d., 40mg daily of zinc, paracetamol 1g t.i.d and 1g daily of Vitamin C. A nutritious diet plan was instituted. A qualified psychiatrist provided psycho-social support.

His temperature subsided on day 3. On day 5, his liver enzymes increased with the AST rising to over 5 times the upper limit of normal (Table 1). He however had no symptoms or signs of liver disease. HRZE was suspended and he was given a hepato-protective drug. His liver panel on day 10 showed significant improvement in liver enzymes. HRZE was re-started at a lower dose of 2 tablets daily and later (day 14) scaled up to 3 tablets after checking the liver enzymes.

The patient’s clinical picture improved gradually. Nasal wash and rectal swab samples were taken for SARS – CoV-2 RNA tests following completion of hydroxychloroquine and the result came back negative. ECG was also normal. He was discharged on day 18 to continue TB therapy and start ART on outpatient basis.

### Table 1 Laboratory finds of the patients

| Laboratory parameters | Patient 1 | Patient 2 | Patient 3 |
|-----------------------|-----------|-----------|-----------|
|                       | Baseline result | Day 12 | Baseline result | Day 5 | Baseline result | Day 5 | Day 10 |
| Haemoglobin (11.5-16.0g/dl) | 9.3 | 8.7 | 7.1 | 11 | 7.7 | 8.5 |
| Mean corpuscular volume (78.0-100.0 fl) | 67.6 | 64.4 | 76.7 | 71.8 | 72.2 | 73.1 |
| Mean corpuscular haemoglobin (26.0-34.0pg) | 22.6 | 22 | 27.1 | 25.6 | 26.5 | 25.4 |
| Neutrophils (1.5-6.6 x 10³/microlit) | 4.46 | 6.7 | 2.62 | 8.64 | 3.96 | 3.1 |
| Lymphocytes (0.8 – 4 x 10³/microlit) | 2.09 | 1.78 | 1.8 | 0.87 | 0.51 | 1.19 |
| Platelet count (140-440 x10³/microlit) | 374 | 187 | 44 | 87 | 100 | 115 |
| Alanine transaminase (0-40 U/L) | 19.4 | 26.3 | 18.9 | 27.1 | 60.5 | 50.9 | 62.6 |
| Aspartate transaminase (0-41 U/L) | 51.1 | 27.3 | 22.1 | 23.5 | 73.1 | 276.9 | 69.9 |
| Albumin (35-52 g/L) | 22.9 | 25.1 | 20.5 | 22.7 | 30.4 | 27.7 | 28.9 |
| Urea (2.5 – 8.3mmol/l) | 5.1 | 2.4 | 1 | 2.6 | 27.4 | 25.6 | 6 |
| Creatinine (44-166 micromol/l) | 33 | 65 | 69 | 61 | 545 | 382 | 88 |
| HV antibodies | Positive (type 1) | Positive (type 1) | Positive (type 1) |
| CD4 count (cells/microlit) | 78 | 156 | 16 |
| Viral load (copies/ml) | 27,210 | 200,008 | 9,838,407 |

### DISCUSSION

There is still some debate about the clinical outcomes of PLWH with COVID-19 co-infection. Some authors reported that PLWH did not have more severe disease or worse outcomes compared to their HIV negative counterparts. However, their cohorts were mostly patients with controlled HIV on ART and this may have influenced their findings.

Yang et al in a case report of an HIV patient with opportunistic infection, CD4 count of 21 cells/mm³ and COVID-19 documented that the patient was asymptomatic, had normal chest CT scan findings and a positive outcome. The HIV patients in our case series similarly had low CD4 counts, opportunistic infections - Kaposi’s sarcoma, pulmonary tuberculosis and fungal infection and were also virally unsuppressed. None of them had a severe clinical course or fatal outcome.

The favourable clinical picture observed in our case series and the aforementioned studies is speculated to be as a result of the protection against the cytokine storm conferred by the dysfunctional cellular immune response evident in PLWH. This response hinders the release of cytokines and other inflammatory markers so preventing pronounced inflammation and consequent lung and multi-organ damage.

A large, population based, cohort study from South Africa however reported poor outcomes with an increased mortality from COVID-19 in PLWH regardless of viral suppression. In comparison to the patients in our series, these patients had other comorbidities, notably diabetes mellitus and hypertension, which may have contributed to the undesirable outcomes. Karmen-Tuohy et al reported on a cohort with similar co-morbidities as those in the South African study but in the latter case the patients had tuberculosis in addition which may have contributed to the unfavourable outcomes.

All patients received hydroxychloroquine as part of the standard of care with good response and no record of arrhythmias.

Copyright © The Author(s). This is an Open Access article under the CC BY license.
Patient 2 was managed with anti-TB medication in addition with clinical improvement although GeneXpert did not detect mycobacterium tuberculosis. Empirical therapy was given on the basis of a suggestive clinical picture and chest X-ray findings because despite its high sensitivity, GeneXpert may give a false negative result in 14-30% of cases as reported in other studies.12,13

CONCLUSION
In conclusion, our reports showed a favourable disease course and outcome of COVID-19 in three PLWH with advanced HIV in Ghana. This implies that this population may not have a more deleterious COVID-19 course or outcome compared to their HIV negative counterparts. However, this is a case series involving only 3 patients and the findings should be interpreted with caution. More in-depth studies are needed to further elucidate the impact of COVID-19 on morbidity and mortality in PLWH with advanced immunosuppression.

ACKNOWLEDGEMENT
We thank the clinical, laboratory, technical and all other staff working at the HIIU at the Komfo Anokye Teaching Hospital in Kumasi, Ghana for their dedicated contribution to the fight against COVID-19. We are also grateful to the patients whose data we used.

REFERENCES
1. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020 Jun;80(6):639–45.
2. Rajesh T. Gandhi MD. Respiratory Viral Infections in HIV-Infected Patients. NEJM J Watch [Internet]. 2008 Apr 2 [cited 2020 Sep 2];2008. Available from: https://www.jwatch.org/ID2008040200000004/2008/04/02/respiratory-viral-infections-hiv-infected
3. Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M, et al. Severe Influenza-associated Respiratory Infection in High HIV Prevalence Setting, South Africa, 2009–2011 - Volume 19, Number 11—November 2013 - Emerging Infectious Diseases journal - CDC. [cited 2020 Sep 2]; Available from: https://wwwnc.cdc.gov/eid/article/19/11/13-0546_article
4. del Amo J, Polo R, Moreno S, Diaz A, Martinez E, Arribas JR, et al. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. Ann Intern Med [Internet]. 2020 Jun 26 [cited 2020 Sep 2]; Available from: https://www.acpjournals.org/doi/10.7326/M20-3689
5. Karmen-Tuohy S, Carlucci PM, Zacharioudakis IM, Zervou FN, Rebick G, Klein E, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. medRxiv. 2020 May 12;2020.05.07.20094797.
6. Sigel K, Swartz T, Golden E, Paranjpe I, Somani S, Richter F, et al. Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. Clin Infect Dis [Internet]. [cited 2020 Sep 2]; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa880/5864410
7. Guo W, Weng H, Bai H, Liu J, Wei X, Zhou K, et al. [Quick community survey on the impact of COVID-19 outbreak for the healthcare of people living with HIV]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Mar 30;41(5):662–6.
8. Yang R, Gui X, Gao S, Mo P, Ke H, Zhang Y, et al. The reflection on an AIDS patient with asymptomatic COVID-19 - Abstract - Europe PMC. Res Sq [Internet]. 2020 [cited 2020 Sep 2]; Available from: https://europepmc.org/article/ppr/ppr129367
9. Davies M-A. HIV and risk of COVID-19 death: a population cohort study from the Western Cape Province, South Africa. medRxiv [Internet]. 2020 Jul 3 [cited 2020 Aug 21]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340198/
10. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med [Internet]. 2020 Apr 27 [cited 2020 May 27];0(0). Available from: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30216-2/abstract
11. Toombs J, Van den Abbeele K, Democratis J, Mandal AKJ, Missouris CG. Pneumococcal co-infection in Covid-19 patients. J Med Virol [Internet]. 2020 Jul 8 [cited 2020 Sep 2]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361306/
12. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev [Internet]. 2013 [cited 2020 Sep 3];1(1). Available from: https://www.cochranelibrary.com/cdr/doi/10.1002/14651858.CD009593.pub2/abstract
13. Akani MO, Achenbach C, Taiwo B, Idoko J, Ani A, Isa Y, et al. Evaluation of gene xpert for routine diagnosis of HIV-associated tuberculosis in Nigeria: A prospective cohort study. BMC Pulm Med [Internet]. 2017 May 30 [cited 2020 Sep 3];17. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450144/